|
09 Dec 2018 |
Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
|
|
05 Dec 2018 |
CERENIS Announces the Results of TANGO, a Phase III Clinical Study Evaluating CER-001 in Patients with HDL Deficiency
|
|
04 Dec 2018 |
Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
|
|
04 Dec 2018 |
Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
|
|
03 Dec 2018 |
Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
|
|
29 Nov 2018 |
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
|
|
28 Nov 2018 |
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
|
|
28 Nov 2018 |
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
|
|
28 Nov 2018 |
PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
|
|
28 Nov 2018 |
Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
|
|
28 Nov 2018 |
Bayer receives EU approval for its hemophilia A treatment Jivi®
|
|
27 Nov 2018 |
Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies
|
|
27 Nov 2018 |
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
|
|
26 Nov 2018 |
Immune Regulation Announces Positive Results from Phase 1 Clinical Trial of PIN201104
|
|
24 Nov 2018 |
European Commission Approves Pelmeg▼® (pegfilgrastim) as a Biosimilar Treatment to Reduce the Duration of Neutropenia and Incidence of Febrile Neutropenia in Adults Treated with Chemotherapy
|
|
23 Nov 2018 |
Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
|
|
11 Nov 2018 |
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer
|
|
09 Nov 2018 |
Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
|
|
07 Nov 2018 |
Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
|
|
07 Nov 2018 |
New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
|
|
07 Nov 2018 |
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
|
|
07 Nov 2018 |
Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
|
|
03 Nov 2018 |
U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)
|
|
29 Oct 2018 |
Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic
|
|
28 Oct 2018 |
Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin
|
